UK Bioindustry Association (BIA) launches new Genomics Advisory Committee at annual Committee Summit

The UK Bioindustry Association (BIA) launched its newest Advisory Committee, focused on the issue of genomics, chaired by Adrian Ibrahim from the Wellcome Sanger Institute's Innovations team.

UK Bioindustry Association (BIA) launches new Genomics Advisory Committee at annual Committee Summit

Adrian Ibrahim, Head of the Innovations team at the Wellcome Sanger Institute, has become the chair of the new UK Bioindustry Association (BIA) Genomics Advisory Committee
Adrian Ibrahim, Head of the Innovations team at the Wellcome Sanger Institute, has become the chair of the new UK Bioindustry Association (BIA) Genomics Advisory Committee

The BIA has established the Genomics Advisory Committee to support the strategic objective that the UK starts, scales and builds world-leading genomic businesses. Companies and organisations represented on the Committee at its launch include Congenica, Eagle Genomics, Genomics plc, Global Gene Corp, LGC ltd, NewGene ltd, Oxford Nanopore Technologies ltd and the Wellcome Sanger Institute.

The Committee will act as a leadership platform for sharing and discussing issues of common concern between genomic businesses and will provide expert advice on important issues such as the use of data and embedding genomic medicine in the NHS. It has already got off to a flying start through supporting a panel on genomics that the BIA participated with alongside partners in San Francisco in January during the 36th annual JP Morgan Healthcare Conference.

"I am honoured to be the first Chair of this exciting new BIA Advisory Committee. Developments such as the 100,000 Genomes Project and research carried out by the Sanger Institute at the Wellcome Genome Campus in Hinxton Cambridge provide a solid foundation on which UK SMEs can build and grow. The BIA Genomics Advisory Committee will provide strength to the voice of this community.”

Dr Adrian Ibrahim, Chair of the Genomics Advisory Committee and Head of Business Development and Technology Transfer in the Innovations team at the Wellcome Sanger Institute

“I’m delighted to launch the new BIA Genomics Advisory Committee. Genomic medicine is on the brink of transforming healthcare and the UK is at the forefront of this revolution. Convening this group will strengthen the voice of UK industry at an exciting and interesting time for genomics, working to ensure that the UK environment remains supportive and internationally competitive for genomic SMEs.”

BIA Chief Executive, Steve Bates OBE

The Genomics Advisory Committee will be launched at the fourth annual BIA Committee Summit taking place today in London. Over 170 BIA members will gather to discuss key issues of importance to the UK bioscience sector.

The meeting of the Genomics Advisory Committee will take place alongside those of seven other Advisory Committees focussed on the respective issues of Cell and Gene Therapy, Engineering Biology, Finance and Tax, Intellectual Property, Manufacturing, Regulatory Affairs and Science and Innovation.

Notes to Editors

Further information on the BIA Genomics Advisory Committee can be found at: https://www.bioindustry.org/bia-membership/advisory-committees/genomics-advisory-committee.html

Further information on all BIA Advisory Committees can be found at: https://www.bioindustry.org/bia-membership/advisory-committees.html

The full agenda for the 2018 BIA Committee Summit can be found at: https://www.bioindustry.org/event-listing/bia-committee-summit-2018.html

Selected Websites
Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Wellcome Sanger Institute calls for the free movement of scientists across European borders following Brexit

The Institute has provided evidence for the UK Government Science and Technology Committee’s inquiry into an immigration system that works for science and innovation

Genomics offers new treatment options for infants with range of soft tissue tumours

Scientists uncover the genetic changes causing a group of related infant cancers

Genetic discovery will help clinicians identify aggressive versus benign bone tumours

A genetic change affecting the transcription factor, FOS is specific to osteoblastoma, distinguishing it from osteosarcoma